Liminatus is working in close coordination with experienced legal, financial, and regulatory advisors to determine the optimal structure, governance, and compliance framework for the proposed ...

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful ...

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year ...

The transaction is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund ...

Abstracts will be published online via the ESMO website at 00:05 CEST on October 13 th 2025 (6:05 pm ET on October 12 th ). Following the presentations, copies of the presentations will be posted on ...

EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its ...

The CHMP’s recommendation for ZURZUVAE will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the third quarter of 2025. The U.S. FDA ...

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities ...